Congenital polycythemias
Authors:
J. Kučerová 1; M. Horváthová 1; D. Pospíšilová 2; V. Divoký 1,3
Authors‘ workplace:
Ústav biologie LF UP v Olomouci, 2Dětská klinika LF UP a FN v Olomouci, 3HOK FN v Olomouci
1
Published in:
Transfuze Hematol. dnes,15, 2009, No. 4, p. 216-222.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Polycythemia is a condition characterized by increased erythrocyte mass, accompanied by elevated hematocrit, red blood cell count and increased concentration of hemoglobin. Polycythemia may result from increased proliferation or decreased apoptosis of erythroid progenitors, and eventually from delayed erythroid differentiation. In congenital primary polycythemia this is caused by inherited defect in hypoxia sensing or response of hematopoietic progenitors to erythroid growth factors. In congenital secondary polycythemia, resulting from elevated circulating erythropoietic factors, this is mostly due to inherited defect causing high affinity of hemoglobin for oxygen. Biochemical, cellular and molecular biology tests are important for evaluation of polycythemia type and differential diagnostics. Our laboratories at Faculty of Medicine Palacky University and University Hospital in Olomouc have a long-term tradition in congenital polycythemia research. With the identification of several new mutations causing congenital polycythemia and construction of mouse model of familial polycythemia with dominant inheritance we have contributed to better understanding of molecular pathophysiology of this disease. Identification of causative mutations facilitates better and more accurate diagnostics and can even contribute considerably to development of new therapeutic approaches.
Key words:
congenital polycythemia, HIF pathway, EPOR pathway, hypersensitivity to erythropoietin
Sources
1. Cario H. Childhood polycythemias/erythrocytoses: classification, diagnosis, clinical presentation, and treatment. Ann Hematol 2005; 84: 137-145.
2. Prchal JF, Prchal JT. Molecular basis for polycythemia. Curr Opin Hematol 1999; 6: 100–109.
3. Benesch R, Benesch RE, Yu CI. Reciprocal binding of oxygen and diphosphoglycerate by human hemoglobin. Proc Natl Acad Sci U S A 1968; 59: 526-532.
4. Stopka T, Zivny JH, Stopkova P, Prchal JF, Prchal JT. Human hematopoietic progenitors express erythropoietin. Blood 1998; 91: 3766-3772.
5. Lappin TR, Maxwell AP, Johnston PG. EPO’s alter ego: erythropoietin has multiple actions. Stem Cells 2002; 20: 485-492.
6. Halvorsen S, Bechensteen AG. Physiology of erythropoietin during mammalian development. Acta Paediatr Suppl 2002; 91: 17-26.
7. Palis J, Segel GB. Developmental biology of erythropoiesis. Blood Rev 1998; 12: 106-114.
8. Noguchi CT, Asavaritikrai P, Teng R, Jia Y. Role of erythropoietin in the brain. Crit Rev Oncol Hematol 2007; 64: 159-171.
9. Ruifrok WP, de Boer RA, Westenbrink BD, van Veldhuisen DJ, van Gilst WH. Erythropoietin in cardiac disease: new features of an old drug. Eur J Pharmacol 2008; 585: 270-277.
10. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999; 94: 1864-1877.
11. Rankin EB, Biju MP, Liu Q, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest 2007; 4: 1068-1077.
12. Percy MJ, Furlow PW, Lucas GS, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 2008; 358: 162-168.
13. Smith TG, Robbins PA, Ratcliffe PJ. The human side of hypoxia-inducible factor. Br J Haematol 2008; 3: 325-334.
14. Testa U. Apoptotic mechanisms in the control of erythropoiesis. Leukemia 2004; 18: 1176-1199.
15. Chin H, Arai A, Wakao H, Kamiyama R, Miyasaka N, Miura O. Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. Blood 1998; 91: 3734-3745.
16. Larsen L, Röpke C. Suppressors of cytokine signalling: SOCS. APMIS 2002; 110: 833-844.
17. Hilton DJ. Negative regulators of cytokine signal transduction. Cell Mol Life Sci 1999; 55: 1568-1577.
18. Tong W, Zhang J, Lodish HF. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 2005; 105: 4604-4612.
19. Meyer L, Deau B, Forejtníková H, et al. Beta-TRCP mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation. Blood 2007; 109: 5215-5222.
20. Pastore YD, Jelinek J, Ang S, et al. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 2003; 101: 1591-1595.
21. de la Chapelle A, Träskelin AL, Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci U S A 1993; 90: 4495-4499.
22. Gregg XT, Prchal JT. Erythropoietin receptor mutations and human disease. Semin Hematol 1997; 34: 70-76.
23. Kralovics R, Prchal JT. Genetic heterogeneity of primary familial and congenital polycythemia. Am J Hematol 2001; 68: 115-121.
24. Al-Sheikh M, Mazurier E, Gardie B, et al. A study of 36 unrelated cases with pure erythrocytosis revealed three new mutations in the erythropoietin receptor gene. Haematologica 2008; 93: 1072-1075.
25. Petersen KB, Hokland P, Petersen GB, et al. Erythropoietin receptor defect: a cause of primary polycythaemia. Br J Haematol 2004; 125: 537-538.
26. Watowich SS, Xie X, Klingmuller U, et al. Erythropoietin receptor mutations associated with familial erythrocytosis cause hypersensitivity to erythropoietin in the heterozygous state. Blood 1999; 94: 2530-2532.
27. Sokol L, Luhovy M, Guan Y, Prchal JF, Semenza GL, Prchal JT. Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood 1995; 86: 15-22.
28. Percy MJ, Lee FS. Familial erythrocytosis: molecular links to red blood cell control. Haematologica 2008; 93: 963-967.
29. Ang SO, Chen H, Gordeuk VR, et al. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis 2002; 28: 57-62.
30. Perrotta S, Nobili B, Ferraro M, et al. Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: identification of a novel cluster. Blood 2006; 2: 514-519.
31. Pastore Y, Jedlickova K, Guan Y, et al. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am J Hum Genet 2003; 73: 412-419.
32. Bento MC, Chang KT, Guan Y, et al. Congenital polycythemia with homozygous and heterozygous mutations of von Hippel-Lindau gene: five new Caucasian patients. Haematologica 2005; 90: 128-129.
33. Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci USA 2006; 103: 654-659.
34. Percy MJ, Furlow PW, Beer PA, Lappin TRJ, McMullin MF, Lee FS. A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. Blood 2007; 110: 2193-2196.
35. Al-Sheikh M, Moradkhani K, Lopez M, Wajcman H, Préhu C. Disturbance in the HIF-1alpha pathway associated with erythrocytosis: further evidences brought by frameshift and nonsense mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. Blood Cells Mol Dis 2008; 40: 160-165.
36. Martini M, Teofili L, Cenci T, et al. A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica 2008; 93: 1068-1071.
37. Percy MJ, Beer PA, Campbell G, et al. Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood 2008; 111: 5400-5402.
38. Ladroue C, Carcenac R, Leporrier M, et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med 2008; 359: 2685-2692.
39. Indrak K, Wiedermann BF, Batek F, et al. Hb Olomouc or alpha 2 beta 2(86)(F2)Ala— Asp, a new high oxygen affinity variant. Hemoglobin 1987; 11: 151-155.
40. Hoyer JD, Allen SL, Beutler E, Kubik K, West C, Fairbanks VF. Erythrocytosis due to bisphosphoglycerate mutase deficiency with concurrent glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Am J Hematol 2004; 75: 205-208.
41. Lemarchandel V, Joulin V, Valentin C, et al. Compound heterozygosity in a complete erythrocyte bisphosphoglycerate mutase deficiency. Blood 1992; 80: 2643-2649.
42. Jedlickova K, Stockton DW, Prchal JT. Possible primary familial and congenital polycythemia locus at 7q22.1-7q22.2. Blood Cells Mol Dis 2003; 31: 327-331.
43. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002; 16: 1466-1471.
44. Agarwal N, Mojica-Henshaw MP, Simmons ED, Hussey D, Ou CN, Prchal JT. Familial polycythemia caused by a novel mutation in the beta globin gene: essential role of P50 in evaluation of familial polycythemia. Int J Med Sci 2007; 4: 232-236.
45. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
46. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468.
47. Indrak K, Wiedermann B. Novější přístupy k diagnóze a léčbě polycytemických stavů. Vnitř lék 1986; 23: 623-624.
48. Prchal JT, Crist WM, Goldwasser E, Perrine G, Prchal JF. Autosomal dominant polycythemia. Blood 1985; 66: 1208-1214.
49. Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 1997; 90: 2057-2061.
50. Divoky V, Liu Z, Ryan TM, Prchal JF, Townes TM, Prchal JT. Mouse model of congenital polycythemia: Homologous replacement of murine gene by mutant human erythropoietin receptor gene. Proc Natl Acad Sci U S A 2001; 98: 986-991.
51. Divoky V, Prchal JT. Mouse surviving solely on human erythropoietin receptor (EpoR): model of human EpoR-linked disease. Blood 2002; 99: 3873-3875.
52. Yoon D, Bruchova H, Divoky V, Prchal JT. Truncated Human Erythropoietin Receptor Causes Fetal Erythropoiesis with Prolonged Primitive Erythropoiesis. Blood 2009. Odesláno k publikaci.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2009 Issue 4
Most read in this issue
- Congenital polycythemias
- The role of FLT3 mutations in the pathogenesis of acute myeloid leukemia
- Therapy-related myelodysplastic syndrome: a retrospective analysis of data from the Czech Working MDS Group registry
- Allogeneic stem cell transplantations in multiple myeloma patients – single center experience